Contributions
Abstract: P611
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Objective: To evaluate the effectiveness and tolerance of MMF as a first line treatment in a large Caucasian multicentre cohort of NMOSD patients, whatever the AQP4-IgG status.
Methods: Retrospective review of 67 NMOSD patients treated by MMF as first line therapy from the nationwide NOMADMUS cohort. Fifty were female and mean age at disease onset was 37.9 years. 65 patients fulfilled 2015 NMOSD criteria, and 5 were MOG-IgG positive. Effectiveness was evaluated on percentage of patients continuing MMF, percentage of patients free of relapse, pre and post-treatment change of the annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS).
Results: Among 67 patients, 40 (59.7%) continued treatment at last follow-up. Thirty-three (49.3%) were relapse free. The median ARR decreased from 1.0[0.1-3.2] pre-treatment to 0[0-3] post-treatment. Out of 53 patients with complete data about EDSS, the score was improved or stabilized in 44 patients (83%) (p< 0.05). Effectiveness was observed in AQP4-IgG, MOG-IgG, and seronegative NMOSD patients. In 16 patients with associated steroids, 13 (81.2%) continued MMF at the end of follow-up versus 15/28 (53.6%) in the non-steroid group (p=1).
Conclusions and relevance: In this nationwide study, MMF showed effectiveness as a first line therapy in NMOSD, whatever is the AQP4-IgG status. Concomitant use of oral steroids at start could limit the risk of treatment failure.
Disclosure:
Alexis Montcuquet- has received funding for travel from Merck Serono, Teva, Novartis, Sanofi-Genzyme and Biogen
Nicolas Collongues serves on scientific advisory boards for and has received honoraria from Biogen Idec, Merck Serono, Sanofi-Genzyme, Novartis, Teva, Almirall, Bayer Schering Pharma and Alexion Pharmaceutical.
Caroline Papeix serves on scientific advisory boards for Novartis, Sanofi-Genzyme, Roche, Teva has received funding for travel from Novartis and Teva and receives research support from Novartis
Hélène Zéphir received has served for scientific advisory board for Biogen Idec, Teva, Novartis, Bayer, Genzyme, has received research grant support from Teva and Genzyme, and fundings for congresses travels from Biogen Idec, Teva, Novartis, Merck, Bayer, Genzyme, Sanofi.
Bertrand Audoin declares no conflict of interest
David Laplaud declares no conflict of interest
Bertrand Bourre serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Teva
Bruno Brochet serves on scientific advisory boards for and has received honoraria or research support from Biogen Idec, Merck Serono, Sanofi-Genzyme, Novartis, Bayer Schering Pharma, Teva and Roche.
Jean-Philippe Camdessanché receive or have been received fees for lectures, consulting, writing of articles, or training courses from Biogen-Idec, CSL-Behring, Editions Scientifiques L&C, Expression Santé , Laboratoire Français des Biotechnologies, Natus, Merck-Serono, Novartis, Sanofi-Genzyme, Scien, SNF-Floerger, and Teva.
Pierre Labauge- serves on scientific advisory boards for Novartis, Sanofi-Genzyme, has received funding for travel from Novartis and Biogen Idec.
Thibault Moreau serves on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, sanofi-aventis, Genzyme, Roche, Almirall and Teva; has received funding for travel from Merck Serono; and receives research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, sanofi-aventis, Genzyme, Roche, Almirall and Teva.
Bruno Stankoff declares no conflict of interest
Jérôme De Sèze- has served on scientific advisory boards for Biogen Idec, LFB, Merck Serono, sanofiaventis, and Bayer Schering Pharma; and has received research support from Biogen Idec, LFB, Merck Serono, sanofi-aventis, and Bayer Schering Pharma.
Sandra Vukusic- serves on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, sanofi-aventis, and Teva; has received funding for travel from Merck Serono; and receives research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, sanofi-aventis, and Teva.
Romain Marignier - serves on scientific advisory board for MedImmune and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Teva.
Abstract: P611
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Objective: To evaluate the effectiveness and tolerance of MMF as a first line treatment in a large Caucasian multicentre cohort of NMOSD patients, whatever the AQP4-IgG status.
Methods: Retrospective review of 67 NMOSD patients treated by MMF as first line therapy from the nationwide NOMADMUS cohort. Fifty were female and mean age at disease onset was 37.9 years. 65 patients fulfilled 2015 NMOSD criteria, and 5 were MOG-IgG positive. Effectiveness was evaluated on percentage of patients continuing MMF, percentage of patients free of relapse, pre and post-treatment change of the annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS).
Results: Among 67 patients, 40 (59.7%) continued treatment at last follow-up. Thirty-three (49.3%) were relapse free. The median ARR decreased from 1.0[0.1-3.2] pre-treatment to 0[0-3] post-treatment. Out of 53 patients with complete data about EDSS, the score was improved or stabilized in 44 patients (83%) (p< 0.05). Effectiveness was observed in AQP4-IgG, MOG-IgG, and seronegative NMOSD patients. In 16 patients with associated steroids, 13 (81.2%) continued MMF at the end of follow-up versus 15/28 (53.6%) in the non-steroid group (p=1).
Conclusions and relevance: In this nationwide study, MMF showed effectiveness as a first line therapy in NMOSD, whatever is the AQP4-IgG status. Concomitant use of oral steroids at start could limit the risk of treatment failure.
Disclosure:
Alexis Montcuquet- has received funding for travel from Merck Serono, Teva, Novartis, Sanofi-Genzyme and Biogen
Nicolas Collongues serves on scientific advisory boards for and has received honoraria from Biogen Idec, Merck Serono, Sanofi-Genzyme, Novartis, Teva, Almirall, Bayer Schering Pharma and Alexion Pharmaceutical.
Caroline Papeix serves on scientific advisory boards for Novartis, Sanofi-Genzyme, Roche, Teva has received funding for travel from Novartis and Teva and receives research support from Novartis
Hélène Zéphir received has served for scientific advisory board for Biogen Idec, Teva, Novartis, Bayer, Genzyme, has received research grant support from Teva and Genzyme, and fundings for congresses travels from Biogen Idec, Teva, Novartis, Merck, Bayer, Genzyme, Sanofi.
Bertrand Audoin declares no conflict of interest
David Laplaud declares no conflict of interest
Bertrand Bourre serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Teva
Bruno Brochet serves on scientific advisory boards for and has received honoraria or research support from Biogen Idec, Merck Serono, Sanofi-Genzyme, Novartis, Bayer Schering Pharma, Teva and Roche.
Jean-Philippe Camdessanché receive or have been received fees for lectures, consulting, writing of articles, or training courses from Biogen-Idec, CSL-Behring, Editions Scientifiques L&C, Expression Santé , Laboratoire Français des Biotechnologies, Natus, Merck-Serono, Novartis, Sanofi-Genzyme, Scien, SNF-Floerger, and Teva.
Pierre Labauge- serves on scientific advisory boards for Novartis, Sanofi-Genzyme, has received funding for travel from Novartis and Biogen Idec.
Thibault Moreau serves on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, sanofi-aventis, Genzyme, Roche, Almirall and Teva; has received funding for travel from Merck Serono; and receives research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, sanofi-aventis, Genzyme, Roche, Almirall and Teva.
Bruno Stankoff declares no conflict of interest
Jérôme De Sèze- has served on scientific advisory boards for Biogen Idec, LFB, Merck Serono, sanofiaventis, and Bayer Schering Pharma; and has received research support from Biogen Idec, LFB, Merck Serono, sanofi-aventis, and Bayer Schering Pharma.
Sandra Vukusic- serves on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, sanofi-aventis, and Teva; has received funding for travel from Merck Serono; and receives research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, sanofi-aventis, and Teva.
Romain Marignier - serves on scientific advisory board for MedImmune and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Teva.